How Effective Is Immunotherapy in Treating Lung Cancer
When you hear about immunotherapy for lung cancer, it can sound like a breakthrough that works for everyone, but it doesn’t. These treatments have transformed outcomes for some people, yet many still respond better to chemotherapy or targeted drugs. You’ll see response rates that look impressive on paper, but they come with important caveats: tumor type, biomarkers, and long‑term benefit all matter. To understand what those numbers really mean for you…
How Well Does Lung Cancer Immunotherapy Work Overall?
For many people with lung cancer, immunotherapy has expanded treatment options, but its effectiveness varies. Survival outcomes have improved for some groups, yet not all patients respond, and durable long-term remissions are still relatively uncommon.
In advanced non–small cell lung cancer, a proportion of patients experience tumor shrinkage or disease stabilization, and some live significantly longer than would have been expected before these treatments were available. In major clinical trials, approximately 20% of patients were alive at five years.
In small-cell lung cancer, adding immunotherapy to chemotherapy has been shown to modestly extend overall survival, although long-term cures remain rare.
For patients considering immunotherapy as part of their lung cancer treatment, consulting an experienced specialist like Dr. James Wilson is essential.
He and his team are highly regarded experts in thoracic oncology and can provide personalized guidance on whether immunotherapy is appropriate and how it may fit into a comprehensive treatment plan. To learn more, check out their website:
How Well Does Immunotherapy Work in NSCLC?
In non–small cell lung cancer (NSCLC), immunotherapy can be more effective than standard chemotherapy for appropriately selected patients, but outcomes vary.
In tumors with PD‑L1 expression of at least 50%, single‑agent pembrolizumab produces objective responses in roughly 40–45% of patients and has been shown to improve overall survival compared with chemotherapy alone in clinical trials.
When immunotherapy is combined with chemotherapy as first‑line treatment, overall response rates typically increase to about 45–60%, particularly in patients whose tumors have lower PD‑L1 expression.
The benefit from immunotherapy is generally greater in tumors without EGFR or ALK driver mutations and in patients with a history of smoking, likely because these cancers tend to have a higher mutational burden and may be more responsive to immune checkpoint blockade.
What Long-Term Results Can NSCLC Patients Expect?
Although outcomes still vary considerably between individuals, long‑term results with immunotherapy for advanced NSCLC are generally better than those achieved with chemotherapy alone.
Current data suggest that approximately 15–20% of patients treated with immune checkpoint inhibitors are alive at five years, whereas this was uncommon with older treatment approaches.
In patients whose tumors have PD‑L1 expression of 50% or higher, pembrolizumab alone leads to objective responses in roughly 40–45% of cases, and a proportion of these responses can be durable, sometimes lasting several years.
When immunotherapy is combined with chemotherapy, overall response rates increase to approximately 45–60%. This combined approach has been associated with improved survival outcomes in many patients, particularly in those whose tumors don't harbor EGFR or ALK driver mutations.
Does Immunotherapy Help in Small Cell Lung Cancer?
Immunotherapy has had a more limited impact in small cell lung cancer (SCLC) than in many non‑small cell lung cancers, but it has provided a measurable benefit, particularly in extensive‑stage disease. Adding a checkpoint inhibitor such as atezolizumab or durvalumab to standard first‑line platinum‑based chemotherapy leads to a modest improvement in overall survival compared with chemotherapy alone, based on results from large randomized trials.
Most of the initial tumor shrinkage in SCLC still results from chemotherapy, with response rates typically in the range of 60–70%. The main contribution of immunotherapy appears to be in extending survival for some patients and increasing the proportion who experience longer‑term disease control, although this remains a relatively small subset.
Unlike in non‑small cell lung cancer, PD‑L1 expression hasn't been a reliable predictor of benefit from immunotherapy in SCLC, and routine PD‑L1 testing is generally less informative. Current research is focused on evaluating new immunotherapy combinations and novel targets to try to improve outcomes further in this disease.
Who Benefits Most From Lung Cancer Immunotherapy?
Results in small cell lung cancer show that immunotherapy doesn't provide equal benefit to all patients, and this pattern is similar in non–small cell lung cancer (NSCLC).
Patients are more likely to benefit when their tumors have high PD‑L1 expression (typically defined as 50% or higher). In this group, single‑agent pembrolizumab leads to objective responses in roughly 40–45% of patients and has been shown to improve overall survival compared with standard chemotherapy.
For patients with lower PD‑L1 expression, combining immunotherapy with chemotherapy increases response rates to approximately 45–60%, depending on the specific regimen and study.
Clinical outcomes also tend to be better in patients whose tumors don't carry EGFR or ALK driver mutations and in those with a history of smoking, as these tumors often have a higher mutational burden, which is associated with greater sensitivity to immune checkpoint inhibitors.
Side Effects and Quality of Life on Lung Cancer Immunotherapy
Even when the benefits of immunotherapy outweigh its risks, it can cause side effects that affect daily activities. Common issues include fatigue, skin rash, and bowel changes such as colitis and diarrhea. Problems with the thyroid, liver inflammation (hepatitis), and lung inflammation (pneumonitis) may develop slowly, so it's important to report any new or worsening symptoms promptly.
A smaller proportion of patients develop more serious organ inflammation. These reactions can be severe or life‑threatening and may require corticosteroids, other immunosuppressive medications, temporary interruption of immunotherapy, or hospitalization. Regular monitoring, timely input from relevant specialists, and, when appropriate, palliative care support can help manage symptoms and maintain quality of life as much as possible during treatment.
How Lung Cancer Immunotherapy Compares With Chemo and Targeted Drugs
Choosing among immunotherapy, chemotherapy, and targeted drugs for lung cancer depends mainly on tumor characteristics and specific biomarkers.
For advanced non–small cell lung cancer (NSCLC) with PD-L1 expression ≥50% and no targetable driver mutations, single‑agent pembrolizumab leads to response rates of about 40–45% and has been shown to improve overall survival compared with chemotherapy.
In patients with lower PD-L1 expression, combining immunotherapy with chemotherapy generally increases response rates to around 45–60% and provides better outcomes than chemotherapy alone.
In tumors with certain driver mutations, such as EGFR or ALK alterations, targeted therapies are usually preferred as first-line treatment because they tend to produce higher response rates and faster symptom improvement than immunotherapy in this group.
One of immunotherapy’s main strengths is the potential for long-term disease control in a subset of patients. Approximately 15–20% of patients receiving immune checkpoint inhibitors in the metastatic setting are alive at five years in some studies, which is higher than historical outcomes with chemotherapy alone.
Many patients also experience a different side‑effect profile that can be easier to tolerate than standard chemotherapy, although immune‑related toxicities can be serious and require monitoring and prompt management.
Questions to Ask Your Oncologist About Immunotherapy Results
When you meet with your oncologist to review how immunotherapy is working, asking specific questions can help you understand your test results and what they mean for your treatment.
You might ask about:
- Your tumor’s PD‑L1 level and how it influences the likelihood of responding to immunotherapy. For some lung cancers, higher PD‑L1 expression (for example, ≥50%) is associated with higher response rates, sometimes in the range of about 40–45%, depending on the drug and study.
- The results of your molecular testing (such as EGFR, ALK, and other alterations), and how any identified mutation or biomarker affects your treatment options or the role of immunotherapy in your case.
- How the expected response rates compare between immunotherapy alone and combination approaches, such as immunotherapy plus chemotherapy. In some settings, combination therapy may show higher response rates (for example, in the range of roughly 45–60%), though this can vary by cancer type, stage, and specific regimen.
It can also be useful to ask about:
- Your estimated chance of longer‑term disease control and survival (for example, at five years), based on current evidence for your cancer type and treatment.
- The potential immune‑related side effects that may occur with your regimen.
- How side effects and disease response will be monitored (blood tests, imaging schedules, symptom tracking) and what the plan is for managing any complications or adjusting treatment if needed.
Conclusion
Immunotherapy isn’t a miracle cure, but it’s changed what’s possible with lung cancer, especially NSCLC. You’re more likely to benefit if your tumor has high PD‑L1 or certain features your oncologist can test for. While only a minority get long‑term control, some responses are remarkably durable. Ask your care team what realistic goals look like for you, how immunotherapy fits with chemo or targeted drugs, and how you’ll monitor benefits and side effects.